[go: up one dir, main page]

PL1992618T3 - Policykliczna pochodna cynamidowa - Google Patents

Policykliczna pochodna cynamidowa

Info

Publication number
PL1992618T3
PL1992618T3 PL07738023T PL07738023T PL1992618T3 PL 1992618 T3 PL1992618 T3 PL 1992618T3 PL 07738023 T PL07738023 T PL 07738023T PL 07738023 T PL07738023 T PL 07738023T PL 1992618 T3 PL1992618 T3 PL 1992618T3
Authority
PL
Poland
Prior art keywords
polycyclic
cinnamide derivative
derivative
polycyclic cinnamide
cinnamide
Prior art date
Application number
PL07738023T
Other languages
English (en)
Inventor
Teiji Kimura
Noritaka Kitazawa
Toshihiko Kaneko
Nobuaki Sato
Koki Kawano
Koichi Ito
Eriko Doi
Mamoru Takaishi
Takeo Sasaki
Takashi Doko
Takehiko Miyagawa
Hiroaki Hagiwara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of PL1992618T3 publication Critical patent/PL1992618T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL07738023T 2006-03-09 2007-03-08 Policykliczna pochodna cynamidowa PL1992618T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US78051706P 2006-03-09 2006-03-09
JP2006063562 2006-03-09
US86170206P 2006-11-30 2006-11-30
JP2006322728 2006-11-30
PCT/JP2007/054532 WO2007102580A1 (ja) 2006-03-09 2007-03-08 多環式シンナミド誘導体
EP07738023A EP1992618B1 (en) 2006-03-09 2007-03-08 Polycyclic cinnamide derivative

Publications (1)

Publication Number Publication Date
PL1992618T3 true PL1992618T3 (pl) 2012-06-29

Family

ID=38474999

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07738023T PL1992618T3 (pl) 2006-03-09 2007-03-08 Policykliczna pochodna cynamidowa

Country Status (15)

Country Link
EP (1) EP1992618B1 (pl)
KR (1) KR101464651B1 (pl)
AR (1) AR059955A1 (pl)
AU (1) AU2007223158B2 (pl)
CA (1) CA2643796A1 (pl)
CY (1) CY1112767T1 (pl)
EA (1) EA016464B1 (pl)
GE (1) GEP20115139B (pl)
HN (1) HN2008001374A (pl)
HR (1) HRP20120174T1 (pl)
IL (1) IL193770A (pl)
MA (1) MA30268B1 (pl)
MX (1) MX2008011221A (pl)
PL (1) PL1992618T3 (pl)
WO (1) WO2007102580A1 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
KR20080069221A (ko) 2005-11-24 2008-07-25 에자이 알앤드디 매니지먼트 가부시키가이샤 모르폴린 타입의 신나미드 화합물
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
CA2677296A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
DE602008004769D1 (en) 2007-05-11 2011-03-10 Hoffmann La Roche Hetarylaniline als modulatoren für amyloid beta
CA2689948A1 (en) * 2007-06-01 2008-12-18 Schering Corporation Gamma secretase modulators
TW200916469A (en) * 2007-08-31 2009-04-16 Eisai R & Amp D Man Co Ltd Multi-cyclic compounds
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
MX2010006379A (es) * 2007-12-11 2010-09-07 Schering Corp Moduladores de la secretasa gamma.
KR20100135711A (ko) 2007-12-20 2010-12-27 엔비보 파마슈티칼즈, 인코퍼레이티드 사중치환된 벤젠
CA2705411A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
ES2428716T3 (es) 2008-02-22 2013-11-11 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide
MX2011002002A (es) * 2008-08-27 2011-03-29 Eisai R&D Man Co Ltd Proceso para preparar ciertos compuestos de cinnamida.
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ.ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
JP2012508181A (ja) * 2008-11-06 2012-04-05 シェーリング コーポレイション γ−セクレターゼ調節剤
EP2356124A1 (en) * 2008-11-06 2011-08-17 Schering Corporation Gamma secretase modulators
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
JP2012508748A (ja) 2008-11-13 2012-04-12 シェーリング コーポレイション γ−セクレターゼ調節剤
AR074701A1 (es) 2008-12-22 2011-02-02 Schering Corp Moduladores de gamma secretasa
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
EP2401276B1 (en) * 2009-02-26 2013-06-05 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012121809A (ja) * 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
US8703954B2 (en) 2009-02-26 2014-04-22 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
JP2012051805A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
WO2011007756A1 (ja) 2009-07-13 2011-01-20 武田薬品工業株式会社 複素環化合物及びその用途
US8871760B2 (en) * 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
US9145399B2 (en) * 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
US8822699B2 (en) 2010-09-02 2014-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP2014012641A (ja) * 2010-10-29 2014-01-23 Dainippon Sumitomo Pharma Co Ltd 新規ピリジン誘導体
EP2665362B1 (en) * 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
CA2842364A1 (en) 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
ES2655645T3 (es) 2011-07-29 2018-02-21 Karyopharm Therapeutics, Inc. Moduladores de transporte nuclear que contienen hidrazida y usos de los mismos
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
PL3404027T3 (pl) 2012-05-09 2020-09-21 Biogen Ma Inc. Modulatory transportu jądrowego i ich zastosowania
ES2585009T3 (es) 2012-05-16 2016-10-03 Janssen Pharmaceuticals, Inc. Derivados de 3,4-dihidro-2H-pirido[1,2-a]pirazina-1,6-diona sustituidos útiles para el tratamiento de (inter alia) enfermedad de Alzheimer
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
CA2889249C (en) 2012-12-20 2021-02-16 Francois Paul Bischoff Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
LT3010892T (lt) 2013-06-21 2019-04-10 Karyopharm Therapeutics Inc. 1,2,4-triazolai kaip branduolio transporto moduliatoriai ir jų panaudojimas
US10882834B2 (en) 2013-09-20 2021-01-05 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
DK3180331T3 (da) 2014-08-15 2022-09-12 Karyopharm Therapeutics Inc Polymorfer af selinexor
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
CN108699080B (zh) * 2016-02-23 2021-05-14 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288898T1 (de) * 2000-12-04 2005-02-15 Hoffmann La Roche Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
EP1594847A2 (en) * 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
EP1730118A1 (en) * 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
US7667041B2 (en) * 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound

Also Published As

Publication number Publication date
EA016464B1 (ru) 2012-05-30
AR059955A1 (es) 2008-05-14
CY1112767T1 (el) 2016-02-10
AU2007223158B2 (en) 2012-04-12
KR20080108481A (ko) 2008-12-15
EP1992618A1 (en) 2008-11-19
IL193770A0 (en) 2009-05-04
EA200870336A1 (ru) 2009-02-27
CA2643796A1 (en) 2007-09-13
HRP20120174T1 (hr) 2012-03-31
HK1128085A1 (en) 2009-10-16
GEP20115139B (en) 2011-01-10
WO2007102580A1 (ja) 2007-09-13
IL193770A (en) 2012-10-31
KR101464651B1 (ko) 2014-11-24
EP1992618B1 (en) 2012-01-18
HK1122027A1 (en) 2009-05-08
MX2008011221A (es) 2008-09-11
HN2008001374A (es) 2011-03-15
MA30268B1 (fr) 2009-03-02
EP1992618A4 (en) 2010-11-10
AU2007223158A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
IL193770A0 (en) Polycyclic cinnamide derivative
HUS2400041I1 (hu) 4-Pirimidin-szulfamid-származék
HUS1900033I1 (hu) Szubsztituált enaminokarbonil vegyületek
ZA201000474B (en) Polycyclic compound
SI2017278T1 (sl) Derivat dihidropirazolopirimidinona
EP2009005A4 (en) AZOLECARBOXAMIDE DERIVATIVE
IL202262A0 (en) Bicycloaniline derivative
GB0602424D0 (en) Compounds
IL195296A0 (en) Heterocyclic type cinnamide derivative
GB0602046D0 (en) Compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
EP2163554A4 (en) PYRIMIDODIAZEPINONE DERIVATIVE
EP2082022A4 (en) COMPOUNDS
ZA200810499B (en) Ruthenium II compounds
EP2228362A4 (en) 4-HYDROXYPHENYLALKYLAMINE DERIVATIVE
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
ZA200901570B (en) Substituted azolin-2-YL-amino compounds
GB0602042D0 (en) Compounds
GB0600427D0 (en) Compounds
GB0602560D0 (en) Compounds
AU2007906908A0 (en) Leg assembly
GB0602451D0 (en) Compounds
GB0602559D0 (en) Compounds
GB0602134D0 (en) Compounds
GB0600929D0 (en) Compounds